NasdaqGM:CRSPBiotechs
Could CRISPR Therapeutics (CRSP) Pipeline Momentum Reshape Its Position in Gene Editing Leadership?
In the past three months, CRISPR Therapeutics reported strong sales growth for Casgevy, an approved treatment for sickle cell disease and transfusion-dependent beta-thalassemia, along with promising data from its in-vivo candidate CTX310 and a new collaboration with Sirius Therapeutics to advance RNA therapeutics.
This combination of positive clinical and commercial progress points to an expanding product portfolio and increased momentum in the company’s pipeline development efforts.
We'll...